The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
 
Panagiotis A. Konstantinopoulos
Consulting or Advisory Role - Merck; Vertex
 
Steven E. Waggoner
No Relationships to Disclose
 
Gregory A. Vidal
Consulting or Advisory Role - Lilly; Pfizer
Speakers' Bureau - AstraZeneca; Pfizer
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Lilly; Pfizer; Puma Biotechnology; Tesaro
 
Monica M. Mita
Speakers' Bureau - Genentech
 
Gini F. Fleming
Research Funding - Corcept Therapeutics (Inst)
 
Robert W. Holloway
Speakers' Bureau - AstraZeneca; Bard/Davol; Clovis Oncology; Intuitive Surgical; Tesaro
 
Linda Van Le
Consulting or Advisory Role - Biologics, Inc
Research Funding - Amgen; AstraZeneca
 
Jasgit C. Sachdev
Honoraria - Celgene
Consulting or Advisory Role - Celgene
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Celgene
 
Eloise Chapman-Davis
No Relationships to Disclose
 
Gerardo Colon-Otero
Research Funding - Novartis (Inst)
 
Richard T. Penson
Honoraria - Tesaro
Consulting or Advisory Role - Tesaro
Research Funding - Tesaro
Travel, Accommodations, Expenses - Tesaro
 
Ursula A. Matulonis
Consulting or Advisory Role - 2X Oncology; Clovis Oncology; Fujifilm; Geneos; Lilly; Merck; Myriad Genetics
Research Funding - Merck; Novartis
 
Young B. Kim
Stock and Other Ownership Interests - Tesaro (I)
 
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; AstraZeneca (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunogen (Inst); Janssen Oncology (Inst); TESARO (Inst); VBL Therapeutics (Inst)
Research Funding - Lilly (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Elizabeth M. Swisher
Leadership - IDEAYA Biosciences; SAB-Pharma
Research Funding - Clovis Oncology (Inst); Tesaro (Inst)
Expert Testimony - Johnson & Johnson
 
Bruce Jeffrey Dezube
Employment - Tesaro
Stock and Other Ownership Interests - Tesaro
 
Jing Y. Wang
Employment - Amgen (I); Curis; TESARO
Stock and Other Ownership Interests - Amgen (I); Curis; TESARO
Consulting or Advisory Role - Curis
 
Nathan Buerstatte
Employment - Tesaro
Stock and Other Ownership Interests - Tesaro
 
Sujata Arora
Employment - Tesaro
Stock and Other Ownership Interests - Medtronic; Tesaro
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)